Jeffrey B Geske1, Paul M McKie1, Steve R Ommen1, Paul Sorajja2. 1. Department of Internal Medicine, Division of Cardiovascular Diseases, Mayo Clinic College of Medicine, Rochester, Minnesota. 2. Department of Internal Medicine, Division of Cardiovascular Diseases, Mayo Clinic College of Medicine, Rochester, Minnesota. Electronic address: sorajja.paul@mayo.edu.
Abstract
OBJECTIVES: The aim of this study was to determine the relationship between B-type natriuretic peptide (BNP) and survival in patients with hypertrophic cardiomyopathy. BACKGROUND: Natriuretic peptides are released in response to neurohormonal activation, myocardial stretch, and wall tension and therefore reflect hemodynamic derangements. METHODS: A total of 772 patients with hypertrophic cardiomyopathy had BNP obtained in conjunction with echocardiography and clinical evaluation, inclusive of cardiopulmonary exercise evaluation in 429 patients (56%). RESULTS: Survival free of all-cause mortality was lower across increasing levels of BNP (log-rank test, p = 0.002). Three-year survival by tertile was 99.2% (95% confidence interval: 94.3% to 99.9%; BNP level ≤98 pg/ml), 94.8% (95% confidence interval: 88.2% to 97.8%; BNP level, >98 to <298 pg/ml), and 89.9% (95% confidence interval: 82.0% to 94.5%; BNP level ≥298 pg/ml). Compared with patients in the first tertile, the hazard ratios for death in the second and third tertiles were 4.88 (p = 0.006) and 6.98 (p = 0.0003), respectively. This relationship persisted in patients without resting obstructive physiology (n = 497, p = 0.01). BNP levels were related to New York Heart Association functional status (p < 0.0001) and the subsequent need for septal reduction therapy in follow-up (p = 0.04). CONCLUSIONS: In this large cohort of patients with hypertrophic cardiomyopathy, BNP was an independent predictor of morbidity and mortality.
OBJECTIVES: The aim of this study was to determine the relationship between B-type natriuretic peptide (BNP) and survival in patients with hypertrophic cardiomyopathy. BACKGROUND: Natriuretic peptides are released in response to neurohormonal activation, myocardial stretch, and wall tension and therefore reflect hemodynamic derangements. METHODS: A total of 772 patients with hypertrophic cardiomyopathy had BNP obtained in conjunction with echocardiography and clinical evaluation, inclusive of cardiopulmonary exercise evaluation in 429 patients (56%). RESULTS: Survival free of all-cause mortality was lower across increasing levels of BNP (log-rank test, p = 0.002). Three-year survival by tertile was 99.2% (95% confidence interval: 94.3% to 99.9%; BNP level ≤98 pg/ml), 94.8% (95% confidence interval: 88.2% to 97.8%; BNP level, >98 to <298 pg/ml), and 89.9% (95% confidence interval: 82.0% to 94.5%; BNP level ≥298 pg/ml). Compared with patients in the first tertile, the hazard ratios for death in the second and third tertiles were 4.88 (p = 0.006) and 6.98 (p = 0.0003), respectively. This relationship persisted in patients without resting obstructive physiology (n = 497, p = 0.01). BNP levels were related to New York Heart Association functional status (p < 0.0001) and the subsequent need for septal reduction therapy in follow-up (p = 0.04). CONCLUSIONS: In this large cohort of patients with hypertrophic cardiomyopathy, BNP was an independent predictor of morbidity and mortality.
Authors: Tarique Hussain; Andreea Dragulescu; Lee Benson; Shi-Joon Yoo; Howard Meng; Jonathan Windram; Derek Wong; Andreas Greiser; Mark Friedberg; Luc Mertens; Michael Seed; Andrew Redington; Lars Grosse-Wortmann Journal: Pediatr Cardiol Date: 2015-01-21 Impact factor: 1.655
Authors: Kyoung-Min Park; Sung Il Im; Eun Kyoung Kim; Sang-Chol Lee; Seung-Jung Park; June Soo Kim; Young Keun On Journal: PLoS One Date: 2016-06-03 Impact factor: 3.240
Authors: Stephanie B Dixon; Carrie R Howell; Lu Lu; Juan C Plana; Vijaya M Joshi; Russell V Luepker; Jean B Durand; Bonnie Ky; Daniel J Lenihan; John L Jefferies; Daniel M Green; Matthew J Ehrhardt; Daniel A Mulrooney; Timothy E Folse; Robyn E Partin; Aimee K Santucci; Rebecca M Howell; Deo Kumar Srivastava; Melissa M Hudson; Leslie L Robison; Kirsten K Ness; Gregory T Armstrong Journal: Cancer Date: 2020-10-27 Impact factor: 6.921